<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171700</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-100</org_study_id>
    <nct_id>NCT04171700</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes</brief_title>
  <acronym>LODESTAR</acronym>
  <official_title>A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients
      with various solid tumors and with deleterious mutations in Homologous Recombination Repair
      (HRR) genes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response Rate by Investigator</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate by Independent Radiology Review</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Best overall response rate by independent radiology review by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Measure of clinical benefit, defined as the percentage of complete response (CR), partial response (PR), and stable disease (SD) beyond 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Measure of clinical benefit, defined as the duration from study enrollment to objective tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Measure of clinical benefit, defined as the duration from study enrollment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of rucaparib</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Incidence of AEs, clinical lab abnormalities, and dose modifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state minimum concentration [Cmin]</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Rucaparib PK</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Rucaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will be enrolled in either Cohort A or Cohort B.
Cohort A: Up to 200 patients with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.
Cohort B (Exploratory): Up to 20 patients with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).</description>
    <arm_group_label>Rucaparib</arm_group_label>
    <other_name>Rubraca</other_name>
    <other_name>Rucaparib camsylate</other_name>
    <other_name>Rucaparib tablets</other_name>
    <other_name>CO-338</other_name>
    <other_name>PF 01367338</other_name>
    <other_name>AG 014447</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive
             disease

          -  Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate
             cancer)

          -  Have a deleterious mutation (germline or somatic) in BRCA1, BRCA2, PALB2, RAD51C,
             RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. Note: Breast cancer patients that
             are HER2 negative and have germline BRCA1 or BRCA2 mutations AND patients with
             epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or
             metastatic castration-resistant prostate cancer with BRCA1 or BRCA2 mutations are
             ineligible for this trial.

          -  At least one prior line of therapy extending overall survival or standard of care
             therapy for advanced disease. Note: Some tumor types have specific inclusion/exclusion
             criteria for previous treatments.

          -  ECOG 0 or 1

          -  Tumor tissue available for genomic analysis, or must be willing to have a biopsy if no
             archival tumor tissue available

          -  Adequate organ function

          -  Life expectancy of 4 months

        Key Exclusion Criteria:

          -  Active central nervous system brain metastases, leptomeningeal disease or primary
             tumor of CNS origin

          -  Active second malignancy (Exceptions: Successfully treated malignancy with no active
             disease for 1 year, surgically cured and/or low-risk tumors, or patients receiving
             ongoing anticancer hormonal therapy for a previously treated cancer)

          -  Pre-existing gastrointestinal disorders/conditions interfering with
             ingestion/absorption of rucaparib

          -  Prior treatment with a PARP inhibitor

          -  More than 3 prior lines of chemotherapy in the locally advanced/metastatic setting

          -  History of myelodysplastic syndrome or acute myeloid leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Reiss-Binder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clovis Oncology Clinical Trial Information</last_name>
    <phone>1-855-262-3040</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Oncology Clinical Trial Information</last_name>
    <phone>1-303-625-5160</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medicine Hematology and Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer And Blood Specialists</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center - The University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI/Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>78708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rucaparib</keyword>
  <keyword>PARPi</keyword>
  <keyword>rare tumor</keyword>
  <keyword>solid tumor</keyword>
  <keyword>CO-338</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>PARP inhibitor</keyword>
  <keyword>homologous recombination</keyword>
  <keyword>DNA repair</keyword>
  <keyword>LODESTAR</keyword>
  <keyword>germline</keyword>
  <keyword>somatic</keyword>
  <keyword>BRCA1</keyword>
  <keyword>BRCA2</keyword>
  <keyword>PALB2</keyword>
  <keyword>RAD51C</keyword>
  <keyword>RAD51D</keyword>
  <keyword>BARD1</keyword>
  <keyword>BRIP1</keyword>
  <keyword>FANCA</keyword>
  <keyword>RAD51</keyword>
  <keyword>RAD51B</keyword>
  <keyword>sarcoma</keyword>
  <keyword>HRR</keyword>
  <keyword>HRD</keyword>
  <keyword>platinum sensitive</keyword>
  <keyword>platinum resistant</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>tumor agnostic</keyword>
  <keyword>basket study</keyword>
  <keyword>basket trial</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>leiomyosarcoma</keyword>
  <keyword>ampullary carcinoma</keyword>
  <keyword>carcinosarcoma</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

